Pneumococcal Conjugate Vaccine
Links shared publicly online about this topic
Pfizer to supply pneumococcal conjugate vaccines for infants and children
news-medical.net — “Pfizer Inc. today announced it has signed a 10-year Provisional Supply Agreement to supply Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company's 13-valent pneumococcal conjugate vaccine, for infants and young children in the world's poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease.” View full resource at news-medical.net
Most Recently Shared on March 24, 2010 at 5:16 pm By:
Meningitis News: Pfizer to supply pneumococcal conjugate vaccines for infants and children: Pfizer Inc. today anno... http://bit.ly/coSs8Q
Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine (December)
theannals.com — “Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine (December)” View full resource at theannals.com
Most Recently Shared on November 2, 2011 at 3:45 am By:
Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine (December): OBJECTIVE:To review the immunogenicity,... http://t.co/UCOTnIgs
Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research
news-medical.net — “A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.” View full resource at news-medical.net
Most Recently Shared on July 19, 2010 at 5:43 am By:
Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research: A pneumoco... http://bit.ly/ddBw0c
EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13
news-medical.net — “Pfizer Inc. announced today that the European Commission has approved the Company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older.” View full resource at news-medical.net
Most Recently Shared on October 27, 2011 at 12:13 pm By:
Meningitis News: EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13: Pfizer Inc. announced today t... http://t.co/Tf9d5WUY
Pneumococcal conjugate vaccines effective at preventing child deaths, study suggests
feeds.sciencedaily.com — “A new study concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and X-ray defined pneumonia, were also effective against child deaths. According to the review, 80 percent of children were less likely to develop vaccine-type IPD, 58 percent all-serotype IPD, and 27 percent x-ray defined pneumonia than children who did not receive the vaccine. Eleven percent of child deaths were also prevented.” View full resource at feeds.sciencedaily.com
Most Recently Shared on November 18, 2009 at 1:12 am By:
Pneumococcal Conjugate Vaccines Effective At Preventing Child Deaths, Study Suggests: A new study concludes that pn... http://bit.ly/4AUOBj
FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine
news-medical.net — “Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13" (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's 13-valent pneumococcal conjugate vaccine.” View full resource at news-medical.net
Most Recently Shared on February 25, 2010 at 5:38 am By:
FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine: Pfizer Inc. announced today that the United State... http://bit.ly/bOQF86
Pneumococcal conjugate vaccination and nasopharyng... [JAMA. 2010] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on September 27, 2010 at 4:05 am By:
Jay Gordon, MD, FAAP Pediatrician, Health Communicator, Physician, and Doctor
RT @nicolebeth: @JayGordonMDFAAP bf baby need PCV13 to protect from 19A since sibs rec'd PCV7? http://bit.ly/cjCaJQ New vaccine. Wait.
MD Consult: News: Panel reviews recommendations for 13-valent pneumococcal conjugate vaccine
mdconsult.com — “MD Consult: News: Panel reviews recommendations for 13-valent pneumococcal conjugate vaccine” View full resource at mdconsult.com
Most Recently Shared on October 23, 2009 at 10:54 am By:
MD Consult Health Site and Medical Publisher
Panel reviews recommendations for 13-valent pneumococcal conjugate vaccine http://bit.ly/3qbXWs
Sinovac Biotech Submits Clinical Trial Application To SFDA For Pneumococcal Conjugate Vaccine (PCV) - QualityPoint Technologies
qualitypointtech.net — “Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011. Sinovac initiated its PCV research program in 2008. The vaccine targets infants under two years old. The target population in Chinais estimated at 34 million...” View full resource at qualitypointtech.net
Most Recently Shared on March 5, 2011 at 2:35 pm By:
Sinovac Biotech Submits Clinical Trial Application To SFDA For Pneumococcal Conjugate Vaccine (PCV): Sinovac Biote... http://bit.ly/eTC5BO
WHO grants prequalification to Prevenar 13, Pfizer's 13-valent pneumococcal conjugate vaccine for infants & young children - Biotechnology
pharmabiz.com — “The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks” View full resource at pharmabiz.com
Most Recently Shared on August 24, 2010 at 11:13 am By:
WHO grants prequalification to Prevenar 13, Pfizer's 13-valent pneumococcal conjugate vaccine for infants & young ... http://bit.ly/an8GLZ
Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine
cdc.gov — “Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine” View full resource at cdc.gov
Most Recently Shared on December 10, 2010 at 2:52 pm By:
HealthTrendster Health Executive
RECOMMENDATIONS AND REPORTS: Prevention of Pneumococcal Disease Among Infants and Children… http://goo.gl/fb/p6HR3
Serum and Merck Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine - Drugs.com MedNews
drugs.com — “From ENP Newswire (August 8, 2011) ENP Newswire - 08 August 2011 Release date- 05082011 - Serum Institute of India Ltd and Merck (known outside the United State” View full resource at drugs.com
Most Recently Shared on August 8, 2011 at 1:08 pm By:
Drugs and Devices OW OW Health
Serum and Merck Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vacci... http://bit.ly/ofqxY1 #drug
Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV) - Drugs.com MedNews
drugs.com — “Aug 3, 2011 - Merck (NYSE MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced today an a” View full resource at drugs.com
Most Recently Shared on August 3, 2011 at 2:09 pm By:
Drugs and Devices OW OW Health
Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conju... http://bit.ly/qrFjgU #drug
Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older - Dec 22, 2010
pfizer.mediaroom.com — “Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older - Dec 22, 2010” View full resource at pfizer.mediaroom.com
Most Recently Shared on December 22, 2010 at 7:50 pm By:
Pfizer submits applications to FDA and EMA for use of its pneumococcal conjugate vaccine in adults 50 and older: http://bit.ly/g6Z07K
World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children - Aug 23, 2010
pfizer.mediaroom.com — “World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children - Aug 23, 2010” View full resource at pfizer.mediaroom.com
Most Recently Shared on August 23, 2010 at 4:08 pm By:
Latest news from Pfizer: http://bit.ly/9vPfUt
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest Meningitis news and research via News-Medical.Net
-
The Annals
The Annals of Pharmacotherapy is a peer-reviewed medical journal advancing drug therapy by publishing evidence-based pharmacy research and clinical reviews.
-
News-Medical.Net
Medical News from Around the World
Advertisement
